Clinical Trial Update: A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating the combination of Sacituzumab Tirumotecan in patients with unresectable, locally advanced, recurrent, or metastatic eso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING